Sign up for our daily briefing
Make your busy days simpler with Axios AM/PM. Catch up on what's new and why it matters in just 5 minutes.
Catch up on coronavirus stories and special reports, curated by Mike Allen everyday
Catch up on coronavirus stories and special reports, curated by Mike Allen everyday
Denver news in your inbox
Catch up on the most important stories affecting your hometown with Axios Denver
Des Moines news in your inbox
Catch up on the most important stories affecting your hometown with Axios Des Moines
Minneapolis-St. Paul news in your inbox
Catch up on the most important stories affecting your hometown with Axios Twin Cities
Tampa Bay news in your inbox
Catch up on the most important stories affecting your hometown with Axios Tampa Bay
Charlotte news in your inbox
Catch up on the most important stories affecting your hometown with Axios Charlotte
Pfizer's over-the-counter products include Advil. Photo: Roberto Machado Noa/LightRocket via Getty Images
Pfizer and GlaxoSmithKline intend to combine their respective businesses that sell over-the-counter products and then spin out the merged company into its own publicly traded entity, the companies said Wednesday. GSK would own 68% of the company, and Pfizer would own the other 32%.
Why it matters: GSK previously pulled out of buying Pfizer's consumer business. This deal would heavily consolidate common health products — ranging from Pfizer's Advil and Nexium to GSK's Aquafresh toothpaste, Excedrin and Tums — into one $13 billion drug giant.